Dulaglutide Prevents Some Adverse Cardiovascular Outcomes in Patients with Diabetes

In relatively healthy diabetic patients, this drug showed promise for primary prevention.

Glucagon-like peptide-1 (GLP-1) agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors prevent some adverse cardiovascular (CV) events in middle-aged patients with glycosylated hemoglobin (HbA_1c) levels >8.0%. In trials with primary CV outcomes, liraglutide and semaglutide also prevented some prespecified chronic renal outcomes.

In another manufacturer-sponsored study, researchers randomized 9900 patients with type 2 diabetes (mean age, 66; median HbA_1c level, 7.2%) and known CV disease or CV risk factors to receive weekly subcutaneous injections of dulaglutide (Trulicity; 1.5 mg) or placebo. After median follow-up of 5.4 years, significantly fewer patients taking dulaglutide reached a composite CV endpoint (i.e., nonfatal myocardial…

Reviewing Author

Bruce Soloway, MD

Disclosures

Editorial BoardsNew RoAR News (http://www.newroarnews.org)

Bruce Soloway, MD

Disclosures

Editorial BoardsNew RoAR News (http://www.newroarnews.org)

Dulaglutide Prevents Some Adverse Cardiovascular Outcomes in Patients with Diabetes

Topics

Reviewing Author